A Clinical Study to Evaluate Subcutaneously Delivered Long-Acting MASP-2 Inhibitor OMS1029
Latest Information Update: 16 Aug 2022
At a glance
- Drugs OMS 1029 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Omeros Corporation
- 09 Aug 2022 According to an Omeros Corporation media release, first dose administered earlier this week.
- 10 May 2022 According to an Omeros Corporation media release, enrollment is targeted to begin this summer.
- 01 Mar 2022 According to an Omeros Corporation media release, based on PK/PD data to date, dosing in humans is expected to be once-monthly to once-quarterly by subcutaneous or intravenous administration.